The Effects of Lowering LDL Cholesterol with Statin Therapy in People at Low Risk of Vascular Disease: Meta-Analysis of Individual Data from 27 Randomised Trials  by unknown
L
t
C
s
p
t
p
f
3
m
c
r
t
o

e
L
0
T
p
a
w
e
0
0
s
v
r
r
m
r
t
c

a
d
e
o
JOURNAL OF VASCULAR SURGERY
January 2013284 Abstractsat least one screening question were considered at high risk for falls, and all
others were considered low risk for falls. This was based on the fact that
previous data have indicated patients who have fallen in the past year would
have a positive likelihood ratio of future falls ranging from 2.3 to 2.8, and
patients who have not fallen in the past year but who had gate, balance, or
mobility problems would have a positive likelihood ratio of future falls
ranging from 1.7 to 2.4 (Ganz DA, JAMA 2007;297:77-86). Of 515
patients enrolled, 35 had a first major bleed during follow-up (incidence rate
of 7.5/100 patient-years). There were 308 patients (59.8%) who were at
high risk of falls, and these patients had a nonsignificantly higher crude
incidence rate of major bleeding than patients at low risk of falls (8.0 vs
6.8/100 patient-years, P .64).Withmultivariate analysis, high fall risk was
not statistically associated with the risk of a major bleed (hazard risk, 1.09;
95% confidence interval, 0.54-2.21). Only three major bleeds occurred
directly after a fall, for an incidence rate of 0.6/100 patient-years.
Comment: The obvious criticism of this study is that patients consid-
ered at high fall risk by their physicians may never have been eligible for
enrollment in this study because decisions may have been made to withhold
anticoagulants in such patients. A second potential weakness is that the
screening questions may overestimate risk of falls. Also, the investigators did
not actually count the total number of falls that occurred during follow-up.
Finally, patients with severe cognitive impairment, who are arguably also at
high risk of falls, were excluded from the study. However, one cannot argue
with the fact that only threemajor bleeds occurred directly after a known fall.
Perhaps a better conclusion would be that falls themselves are over empha-
sized as a risk factor for major bleeds in patients on anticoagulants.
The Effects of Lowering LDL Cholesterol with Statin Therapy in
People at Low Risk of Vascular Disease: Meta-Analysis of Individual
Data from 27 Randomised Trials
Cholesterol Treatment Trialist (CTT) Collaborators. Lancet 2012;380:
581-90.
Conclusion: In patients at low risk of vascular disease, the benefit of
statin therapy in lowering low-density lipoprotein (LDL) cholesterol greatly
exceeds known hazards of statin therapy. Present guidelines for statin
therapy may need to be reconsidered.
Summary: In a previous analysis by the Cholesterol Treatment Trialist
(CTT) collaboration, reduction of LDL cholesterol with statins in subjects
with no previous history of vascular disease reduced the risk of major vascular
events by one-fifth (Cholesterol Treatment Trialist [CTT] Collaboration,
S
tancet 2010:376:1670-81). However, there was uncertainty whether statin
herapy was of overall net benefit in primary prevention (Taylor F, et al,
ochrane Database Syst Rev 2012;1:CD004816). The current meta-analy-
is was designed to evaluate the net effects of cholesterol reduction in
atients at low risk of vascular events. Individual participant data from 22
rials of statins vs controls were used. There were 134,537 individual
articipants (mean LDL cholesterol difference of 1.08 mmol/L; median
ollow-up, 4.8 years). There were five trials of more vs less statin medication,
9,612 participants with a mean LDL cholesterol difference of 0.51
mol/L, and a mean follow-up of 5.1 years. Major vascular events or major
oronary events were defined as nonfatal myocardial infarction, coronary-
elated death, stroke, or coronary revascularization. Participants on control
herapy (no statin or low-intensity statin) were separated into five categories
f baseline 5-year major vascular event risk (5%, 5% to 10%, 10% to
20%, 20% to 30%, and 30%). In each category, the rate ratio (RR) for
ach 1.0-mmol/L LDL cholesterol reduction was estimated. Reduction of
DL cholesterol with statins reduced the risk of major vascular events (RR,
.79; 95% confidence interval [CI], 0.77-0.81 per 1.0-mmol/L reduction).
his was largely independent of age, sex, baseline LDL cholesterol, or
revious vascular disease. The reduction in major vascular events was at least
s big in the two lowest risk categories as in the higher risk categories. There
ere significant reductions in the two lowest risk categories for coronary
vents (RR, 0.57; 99% CI, 0.36-0.89; P  .0012, and RR, 0.61; 99% CI,
.50-0.74; P .0001) and in coronary revascularizations (RR, 0.52; 99%CI
.35-0.75; and RR, 0.63; 99% CI, 0.51-0.79; P  .0001). With regard to
troke, the reduction in risk for participants with a10% 5-year risk of major
ascular events was also similar to that seen in higher risk categories. Statins
educed the risk of vascular mortality (RR per 1.0-mmol/L LDL cholesterol
eduction, 0.85; 95% CI, 0.77-0.95) and all-cause mortality (RR per 1.0
mol/-LDL cholesterol reduction, 0.91; 95%CI, 0.85-0.97). Proportional
eductions were similarly stratified for baseline risk. There was no evidence
hat a reduction in LDL cholesterol with a statin increased the incidence of
ancer, cancer mortality, or other nonvascular mortality.
Comment: Statins appear to be effective and safe for people with a
10% 5-year risk of vascular events. Whereas some data indicate statins are
ssociated with a small excess of hemorrhagic strokes and an increase in
iabetes, the data presented here suggest any long-term effects of small
xcesses of hemorrhagic strokes or diabetes associated with statin therapy are
verwhelmed by statin-dependent reductions in cardiovascular events.
trong consideration needs to be given to rewriting guidelines of cholesterol
herapy for primary prevention of vascular disease.
